Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carmen Salmon

Physician Assistant Roanoke, VA Physician Assistant

NPI 1053644245 CMS profile 10610685

65 Applewood Dr, Roanoke, VA 24019

Open in the dashboard

General payments

$10,386

152 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Salmon of Roanoke, VA is reported in the CMS Open Payments database as having received $10,386 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,573 20
2024 General $2,377 34
2023 General $1,450 20
2022 General $3,871 57
2021 General $1,114 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Salmon
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Carmen Salmon were reported at $1,573. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Carmen Salmon Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,114 $132 $37–$438 $132
2022 $3,871 $155 $48–$522 $149
2023 $1,450 $167 $52–$557 $160
2024 $2,377 $178 $55–$600 $164
2025 $1,573 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $2,662 46 payments
  2. Edwards Lifesciences Corporation $2,592 39 payments
  3. Medtronic, Inc. $2,167 23 payments
  4. iRhythm Technologies, Inc. $1,328 15 payments
  5. Abbott Laboratories $588 16 payments
  6. W. L. Gore & Associates, Inc. $383 4 payments
  7. Cardiac Dimensions, Inc. $299 2 payments
  8. AstraZeneca Pharmaceuticals LP $147 2 payments
  9. Novo Nordisk Inc $113 1 payment
  10. Pfizer Inc. $57 3 payments
  11. Other $50 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,083 139 payments
  2. Travel and Lodging $2,302 12 payments
  3. Education $1 1 payment
Products named General payments · program years 2021–2025
  1. COREVALVE EVOLUT R $1,895 20 payments
  2. WATCHMAN FLX $1,795 21 payments
  3. ZIO XT Patch $1,328 15 payments
  4. WATCHMAN Access System $588 20 payments
  5. SAPIEN 3 Ultra RESILIA $584 8 payments
  6. Zio monitor $522 6 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $436 6 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $400 18 payments
  9. MitraClip System $391 10 payments
  10. GORE CARDIOFORM Septal Occluder $383 4 payments
  11. Other $1,175 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

427

Median for Physician Assistant: 241

Drug cost

$90,873

Median for Physician Assistant: $4,110

Branded share of claims

32.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 44 $46,059
Jardiance Empagliflozin Brand 39 $34,853
Entresto Sacubitril/Valsartan Brand 14 $7,753
Metoprolol Succinate Generic 39 $535
Clopidogrel Clopidogrel Bisulfate Brand 32 $284
Carvedilol Generic 40 $279
Furosemide Generic 54 $234
Amlodipine Besylate Generic 22 $217
Metoprolol Tartrate Generic 17 $178
Klor-Con M20 Potassium Chloride Brand 11 $153

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$16,066

Medicare's payments for the services billed

Medicare patients

251

Average age 80

Services billed

283

125 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 63%
Arthritis 61%
Ischemic heart disease 60%
Atrial fibrillation 54%
Diabetes 47%
Chronic kidney disease 47%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record